Aflibercept, sold under the brand names Eylea among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It...
26 KB (1,884 words) - 19:14, 28 June 2024
degeneration (AMD) meeting the primary efficacy endpoint of non-inferiority to aflibercept in mean change in best corrected visual acuity (BCVA) from baseline to...
14 KB (1,121 words) - 07:47, 19 June 2024
Schleifer and scientist George Yancopoulos in 1988. Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is...
26 KB (2,269 words) - 18:39, 5 July 2024
biotechnology company, to develop Regeneron's VEGF-inhibiting drug, aflibercept, which was then in Phase I clinical trials. Aventis invested $45 million...
91 KB (8,756 words) - 11:39, 28 June 2024
against aflibercept. Both studies reached its primary endpoints and showed that faricimab given at up to every 16 weeks was non-inferior to aflibercept administered...
20 KB (1,543 words) - 06:38, 10 March 2024
cycle. FOLFIRI is often[citation needed] combined with bevacizumab, aflibercept, cetuximab or panitumumab to improve efficacy and response rate. In the...
4 KB (411 words) - 21:05, 6 May 2024
by diabetes and/or retinal vein occlusion. On July 29, 2014, Eylea (aflibercept), an intravitreal injection produced by Regeneron Pharmaceuticals Inc...
16 KB (1,554 words) - 21:17, 30 October 2023
the macula – benefit most from eye injections of anti-VEGF therapies aflibercept, bevacizumab, or ranibizumab. There is no widely accepted dosing schedule...
50 KB (5,505 words) - 19:50, 4 July 2024
MacD, yet remains more costly, as is the more recent (approved in 2011) aflibercept (Eylea). Tests on these treatments are ongoing relative to the efficacy...
14 KB (1,671 words) - 12:47, 23 April 2024
membrane and to reduce formation of Drusen, is in preparation. Ranibizumab, aflibercept, brolucizumab, and faricimab are approved VEGF inhibitors for the treatment...
90 KB (9,840 words) - 15:04, 5 July 2024
pegol Bevacizumab Icrucumab Ramucirumab Ranibizumab Decoy receptors: Aflibercept Others Additional growth factors: Adrenomedullin Colony-stimulating factors...
92 KB (8,667 words) - 19:29, 28 June 2024
(USAN) Afaxin afegostat (USAN, INN) afelimomab (INN) afimoxifene (INN) aflibercept (USAN, INN)) afloqualone (INN) afovirsen (INN) AFP-Cide Afrin Afrinol...
5 KB (338 words) - 04:53, 2 July 2024
development include biosimilars of omalizumab, denosumab, golimumab, aflibercept, vedolizumab, and pembrolizumab. In November 2022, Alvogen and a former...
11 KB (914 words) - 20:13, 22 June 2024
degeneration. Its effectiveness is similar to that of bevacizumab and aflibercept. A 2023 systematic review update found that while ranibizumab and bevacizumab...
32 KB (2,555 words) - 19:17, 28 June 2024
receptor (Bexarotene) Sex steroid (Testolactone) Other/ungrouped Adagrasib Aflibercept Arsenic trioxide Asparagine depleters (Asparaginase#/Pegaspargase) Axicabtagene...
31 KB (2,940 words) - 06:07, 28 February 2024
Antibodies -cept (Fusion) CTLA-4 Abatacept Belatacept TNF inhibitor Etanercept Opinercept Aflibercept Alefacept Rilonacept...
7 KB (299 words) - 13:45, 27 April 2024
receptor (Bexarotene) Sex steroid (Testolactone) Other/ungrouped Adagrasib Aflibercept Arsenic trioxide Asparagine depleters (Asparaginase#/Pegaspargase) Axicabtagene...
34 KB (3,144 words) - 15:34, 1 July 2024
in the retina of the eye and other parts of the body. Drugs such as aflibercept, bevacizumab, ranibizumab, and pegaptanib can inhibit VEGF and control...
40 KB (4,580 words) - 05:24, 3 June 2024
pegol Bevacizumab Icrucumab Ramucirumab Ranibizumab Decoy receptors: Aflibercept Others Additional growth factors: Adrenomedullin Colony-stimulating factors...
150 KB (15,741 words) - 10:52, 27 June 2024
pegol Bevacizumab Icrucumab Ramucirumab Ranibizumab Decoy receptors: Aflibercept Others Additional growth factors: Adrenomedullin Colony-stimulating factors...
31 KB (3,413 words) - 23:30, 21 June 2024
receptor (Bexarotene) Sex steroid (Testolactone) Other/ungrouped Adagrasib Aflibercept Arsenic trioxide Asparagine depleters (Asparaginase#/Pegaspargase) Axicabtagene...
26 KB (2,420 words) - 15:49, 26 June 2024
pegol Bevacizumab Icrucumab Ramucirumab Ranibizumab Decoy receptors: Aflibercept Others Additional growth factors: Adrenomedullin Colony-stimulating factors...
68 KB (5,993 words) - 00:47, 13 July 2024
identified "key growth" products were Xarelto (rivaroxaban), Eylea (aflibercept), Stivarga (regorafenib), Xofigo (radium-223), and Adempas (riociguat)...
119 KB (11,417 words) - 17:40, 3 July 2024
pegol Bevacizumab Icrucumab Ramucirumab Ranibizumab Decoy receptors: Aflibercept Others Additional growth factors: Adrenomedullin Colony-stimulating factors...
5 KB (412 words) - 23:17, 19 June 2023
Verteporfin S01LA02 Anecortave S01LA03 Pegaptanib S01LA04 Ranibizumab S01LA05 Aflibercept S01LA06 Brolucizumab S01LA07 Abicipar pegol S01LA08 Bevacizumab S01LA09...
10 KB (800 words) - 03:10, 20 April 2024
factor receptor inhibitors, of which the three FDA approved ones are aflibercept, cetuximab and panitumumab. The primary difference in the approach to...
145 KB (15,792 words) - 21:07, 28 June 2024
Additional chimeric proteins used for therapeutic applications include: Aflibercept: A human recombinant protein that aids in the treatment of oxaliplatin-resistant...
19 KB (2,305 words) - 05:22, 15 May 2024
receptor (Bexarotene) Sex steroid (Testolactone) Other/ungrouped Adagrasib Aflibercept Arsenic trioxide Asparagine depleters (Asparaginase#/Pegaspargase) Axicabtagene...
17 KB (1,747 words) - 19:53, 17 March 2024
receptor (Bexarotene) Sex steroid (Testolactone) Other/ungrouped Adagrasib Aflibercept Arsenic trioxide Asparagine depleters (Asparaginase#/Pegaspargase) Axicabtagene...
61 KB (6,082 words) - 05:23, 17 June 2024
(2016). "Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept". International Journal of Retina and Vitreous...
16 KB (1,699 words) - 22:49, 9 February 2024